Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.

Lau Q, Scheithauer B, Kovacs K, Horvath E, Syro LV, Lloyd R.

Pituitary. 2010 Dec;13(4):367-79. doi: 10.1007/s11102-010-0249-0. Review.

PMID:
20740317
2.

Treatment of pituitary neoplasms with temozolomide: a review.

Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, Uribe H, Cusimano M, Kovacs K, Horvath E.

Cancer. 2011 Feb 1;117(3):454-62. doi: 10.1002/cncr.25413. Epub 2010 Sep 15. Review.

3.

MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.

Zuhur SS, Tanik C, Karaman Ö, Velet S, Çil E, Öztürk FY, Özkayalar H, Müslüman AM, Altuntaş Y.

Endocrine. 2011 Oct;40(2):222-7. doi: 10.1007/s12020-011-9485-y. Epub 2011 May 15.

PMID:
21792693
4.

Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.

Bengtsson D, Schrøder HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, Rasmussen ÅK, Johannsson G, Hoybye C, van der Lely AJ, Petersson M, Ragnarsson O, Burman P.

J Clin Endocrinol Metab. 2015 Apr;100(4):1689-98. doi: 10.1210/jc.2014-4350. Epub 2015 Feb 3.

PMID:
25646794
5.

MGMT immunoexpression in adamantinomatous craniopharyngiomas.

Zuhur SS, Müslüman AM, Tanık C, Karaman O, Oztürk FY, Ozderya A, Ozkayalar H, Aydın Y, Altuntaş Y.

Pituitary. 2011 Dec;14(4):323-7. doi: 10.1007/s11102-011-0297-0.

PMID:
21318329
6.

MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.

Fealey ME, Scheithauer BW, Horvath E, Erickson D, Kovacs K, McLendon R, Lloyd RV.

Endocr Pathol. 2010 Sep;21(3):161-5. doi: 10.1007/s12022-010-9120-0.

PMID:
20480258
7.

Temozolomide in aggressive pituitary adenomas and carcinomas.

Ortiz LD, Syro LV, Scheithauer BW, Rotondo F, Uribe H, Fadul CE, Horvath E, Kovacs K.

Clinics (Sao Paulo). 2012;67 Suppl 1:119-23. Review.

8.

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.

Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, François P, Jouanneau E, Passagia JG, Bernier M, Cornélius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T.

J Clin Endocrinol Metab. 2010 Oct;95(10):4592-9. doi: 10.1210/jc.2010-0644. Epub 2010 Jul 21.

PMID:
20660056
9.

MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.

Salehi F, Scheithauer BW, Kros JM, Lau Q, Fealey M, Erickson D, Kovacs K, Horvath E, Lloyd RV.

J Neurooncol. 2011 Sep;104(3):647-57. doi: 10.1007/s11060-011-0532-6. Epub 2011 Feb 11.

PMID:
21311951
10.

O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?

Widhalm G, Wolfsberger S, Preusser M, Woehrer A, Kotter MR, Czech T, Marosi C, Knosp E.

Cancer. 2009 Mar 1;115(5):1070-80. doi: 10.1002/cncr.24053.

11.

Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.

Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K.

Hormones (Athens). 2011 Apr-Jun;10(2):162-7.

12.

Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment.

Raverot G, Castinetti F, Jouanneau E, Morange I, Figarella-Branger D, Dufour H, Trouillas J, Brue T.

Clin Endocrinol (Oxf). 2012 Jun;76(6):769-75. doi: 10.1111/j.1365-2265.2012.04381.x. Review.

PMID:
22404748
13.

The role of temozolomide in the treatment of aggressive pituitary tumors.

Liu JK, Patel J, Eloy JA.

J Clin Neurosci. 2015 Jun;22(6):923-9. doi: 10.1016/j.jocn.2014.12.007. Epub 2015 Mar 12. Review.

PMID:
25772801
14.

DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.

Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H, Yamada S, Fujio S, Arita K, Takano K, Tominaga A, Hizuka N, Ikeda H, Osamura RY, Tahara S, Ishii Y, Kawamata T, Shimatsu A, Teramoto A, Matsuno A.

J Clin Endocrinol Metab. 2013 Mar;98(3):1130-6. doi: 10.1210/jc.2012-2924. Epub 2013 Jan 30.

PMID:
23365123
15.

O-6-methylguanine-DNA methyltransferase (MGMT) immunohistochemical expression in pituitary corticotroph adenomas.

Salehi F, Scheithauer BW, Kovacs K, Horvath E, Syro LV, Sharma S, Manoranjan B, Cusimano M.

Neurosurgery. 2012 Feb;70(2):491-6; discussion 496. doi: 10.1227/NEU.0b013e318230ac63.

PMID:
21822153
16.

[The expression of MGMT in pituitary adenomas and its association with tumour aggressiveness].

Jiang XB, Hu B, Fan X, He DS, Mao ZG, Chen M, Zhu YH, Wang HJ.

Sichuan Da Xue Xue Bao Yi Xue Ban. 2013 May;44(3):462-5. Chinese.

PMID:
23898536
17.

MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.

Kovacs K, Scheithauer BW, Lombardero M, McLendon RE, Syro LV, Uribe H, Ortiz LD, Penagos LC.

Acta Neuropathol. 2008 Feb;115(2):261-2. Epub 2007 Oct 10. No abstract available.

PMID:
17926052
18.

Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.

Zhao Y, Xiao Z, Chen W, Yang J, Li T, Fan B.

Mol Med Rep. 2015 Aug;12(2):2313-22. doi: 10.3892/mmr.2015.3664. Epub 2015 Apr 22.

PMID:
25937029
19.

Low immunohistochemical expression of MGMT in ACTH secreting pituitary tumors of patients with Nelson syndrome.

Salehi F, Scheithauer BW, Moyes VJ, Drake WM, Syro LV, Manoranjan B, Sharma S, Horvath E, Kovacs K.

Endocr Pathol. 2010 Dec;21(4):227-9. doi: 10.1007/s12022-010-9138-3.

PMID:
21061089
20.

Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.

Annamalai AK, Dean AF, Kandasamy N, Kovacs K, Burton H, Halsall DJ, Shaw AS, Antoun NM, Cheow HK, Kirollos RW, Pickard JD, Simpson HL, Jefferies SJ, Burnet NG, Gurnell M.

Pituitary. 2012 Sep;15(3):276-87. doi: 10.1007/s11102-011-0363-7. Review.

PMID:
22076588

Supplemental Content

Support Center